Coat the Cornea, See the Difference in the eyes of cystinosis patients

CYSTADROPS dissolves corneal cystine crystals across all layers

40% decrease in corneal cystine crystals after 90 days of use
Efficacy maintained over 5 years with well-managed daily use

With practical, 4 times a day dosing

Cystadrops dissolving corneal cystine crystals

Clinical Data & Safety

REVIEW THE RESULTS

How CYSTADROPS Works

LEARN MORE

Prescribing CYSTADROPS

START HERE

Indications and Usage

CYSTADROPS (cysteamine ophthalmic solution) 0.37% is a cystine-depleting agent indicated for the treatment of corneal cystine crystal deposits in adults and children with cystinosis.

Important Safety Information

To minimize the risk of contamination, do not touch the dropper tip to any surface. Keep bottle tightly closed when not in use.
Benign intracranial hypertension (or pseudotumor cerebri) associated with oral cysteamine or ophthalmic use of cysteamine (with concurrent oral cysteamine) has been reported, which has resolved with diuretic therapy.
Contains benzalkonium chloride. Contact with soft contact lenses should be avoided. Remove contact lenses prior to application. Lenses may be reinserted 15 minutes following administration.
The most common adverse reactions (≥ 10%) are eye pain, vision blurred, eye irritation, ocular hyperaemia, instillation site discomfort, eye pruritus, lacrimation increased, and ocular deposits.
To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases Inc. at 1-888-575-8344, or FDA at 1‑800-FDA-1088 or www.fda.gov/medwatch.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

+ SEE MORE

Important Safety Information

To minimize the risk of contamination, do not touch the dropper tip to any surface. Keep bottle tightly closed when not in use.